8-K: Glucotrack Appoints Neuromodulation Expert Dr. Latif

Glucotrack, Inc. announced the appointment of Dr. Usman Latif, a neuromodulation and painful diabetic neuropathy expert, to its clinical advisory team to advance integrated glucose monitoring applications.

Summary

• Glucotrack, Inc. appointed Dr. Usman Latif, MD, MBA, to its clinical advisory team on October 29, 2025.
• Dr. Latif will provide strategic counsel for the Company's epidural glucose monitoring applications and continuous blood glucose monitor (CBGM).
• His expertise is in neuromodulation and treatment of Painful Diabetic Neuropathy (PDN).
• PDN affects approximately one-fifth of the more than 38 million Americans with diabetes, totaling over 7 million individuals.
• Spinal Cord Stimulation (SCS) is a treatment option for PDN, involving an implanted device with electrodes placed in the epidural space.
• Glucotrack's sensing technology has the potential to integrate into existing SCS devices to measure epidural glucose in PDN patients.
• The Company expanded into epidural glucose monitoring in April 2024.
• A long-term preclinical study demonstrating the feasibility and safety of glucose monitoring in the epidural space has been successfully completed.

Sentiment

Score: 8

Explanation: The announcement is positive, highlighting strategic progress, expert recruitment, and successful preclinical study results in a significant medical area. No negative news or setbacks are reported.

Positives

• Appointment of a highly respected expert, Dr. Usman Latif, to the clinical advisory team, enhancing strategic guidance.
• Dr. Latif's deep expertise in neuromodulation and Painful Diabetic Neuropathy (PDN) aligns directly with Glucotrack's strategic focus on integrated disease management.
• Advancement of integrated glucose monitoring applications, specifically epidural glucose monitoring, for a significant patient population.
• Successful completion of a long-term preclinical study demonstrating the feasibility and safety of glucose monitoring in the epidural space.
• Potential to simplify care, empower physicians with better data, and ultimately improve outcomes for PDN patients by integrating continuous glucose monitoring into spinal cord stimulation.

Risks

• Ability to raise additional capital to finance operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise).
• Risks relating to the receipt and timing of regulatory approvals, including U.S. Food and Drug Administration (FDA) approval.
• Risks relating to enrollment of patients in, and the conduct of, clinical trials.
• Risks relating to future distribution agreements.
• Risks relating to the ability to hire and retain qualified personnel, including sales and distribution staff.
• Additional risk factors described in Glucotrack's filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, as filed on March 31, 2025.

Future Outlook

Glucotrack aims to advance integrated disease and device management solutions for Painful Diabetic Neuropathy (PDN) patients by integrating glucose sensing directly into spinal cord stimulator leads. The Company's vision is to simplify care, empower physicians with better data, and improve outcomes for these patients.

Management Comments

• Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack: "His exceptional knowledge in pain management and product design will be invaluable as we advance integrated disease and device management solutions for PDN patients."
• Dr. Usman Latif: "I'm excited to join Glucotrack's clinical advisory team and help integrate glucose sensing directly into spinal cord stimulator leads."
• Dr. Usman Latif: "For patients with PDN, managing their condition often involves multiple devices and disjointed streams of information. Glucotrack's vision of integrating continuous glucose monitoring into proven pain management therapies like spinal cord stimulation could be a significant advancement in integrated care."
• Dr. Usman Latif: "It's an honor to help guide the development of a technology that could simplify care, empower physicians with better data, and ultimately improve outcomes for these patients."

Industry Context

The appointment of Dr. Latif and Glucotrack's focus on integrating glucose monitoring with Spinal Cord Stimulation (SCS) for Painful Diabetic Neuropathy (PDN) reflects a trend towards more integrated and patient-centric medical device solutions. This approach aims to simplify complex disease management, potentially offering a competitive edge by combining diagnostic and therapeutic functions in a single system, addressing a significant market of over 7 million PDN patients in the U.S.

Comparison to Industry Standards

• The integration of continuous glucose monitoring into spinal cord stimulators for Painful Diabetic Neuropathy (PDN) represents an innovative approach, potentially differentiating Glucotrack from traditional standalone glucose monitoring or pain management device companies.
• While specific comparable integrated solutions are not detailed in the filing, the focus on simplifying care for PDN patients, a condition affecting over 7 million Americans, positions Glucotrack to address a significant unmet need in a novel way.
• The successful completion of a long-term preclinical study for epidural glucose monitoring suggests progress in a specialized area, potentially setting a new standard for integrated device development in neuromodulation and diabetes management.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strategic advancement, expert recruitment, and potential for future market expansion in PDN treatment.
• Patients (with PDN): Potential for improved, simplified, and integrated care through novel technology.
• Physicians: Empowerment with better data for managing PDN patients.
• Employees: Potential for increased morale and focus due to strategic progress and expert collaboration.

Next Steps

• Advance integrated disease and device management solutions for PDN patients.
• Guide the development of technology to integrate glucose sensing directly into spinal cord stimulator leads.
• Continue development of the long-term implantable continuous blood glucose monitoring system (CBGM).
• Seek regulatory approvals (e.g., U.S. Food and Drug Administration).
• Enroll patients in and conduct clinical trials.
• Establish future distribution agreements.

Key Dates

Recommendation

The announcement is a positive strategic development, indicating progress in clinical development and strengthening the advisory team. However, it does not contain immediate financial results or major commercial milestones that would warrant a 'buy' recommendation. The company is still in the development phase for these integrated solutions, and significant risks related to capital, regulatory approvals, and clinical trials remain. Therefore, a 'hold' recommendation is appropriate for investors to observe further progress.

Keywords

Glucotrack, GCTK, Diabetes, Glucose Monitoring, Neuromodulation, Painful Diabetic Neuropathy, PDN, Spinal Cord Stimulation, SCS, Medical Device, Clinical Advisory Team, Usman Latif, Epidural Glucose Monitoring, Continuous Blood Glucose Monitor, CBGM